Personalis (PSNL) has demonstrated exceptional momentum, gaining nearly 250% over the past year.
Shares recently set a new 3-year high.
PSNL stock maintains a 100% “Buy” technical opinion from Barchart.
Despite strong price appreciation, PSNL remains unprofitable and highly speculative, with mixed analyst sentiment and significant short interest.
Today’s Featured Stock
Valued at $1.8 billion, Personalis (PSNL) is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient’s cancer and immune response.
What I’m Watching
I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals and superior current momentum. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. PSNL checks those boxes. The Trend Seeker issued a new “Buy” signal on Aug. 10. Since then, the stock has gained 17.39%.
More News from Barchart
Barchart’s Technical Indicators for Personalis
Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.
Personalis scored a 3-year high of $18.89 on Aug. 21.
Personalis has a Weighted Alpha of 152.59.
PSNL has a 100% “Buy” opinion from Barchart.
The stock has gained 248.16% over the past 52 weeks.
Personalis has its Trend Seeker “Buy” signal intact.
The stock recently traded at $17.02 with a 50-day moving average of $13.65.
PSNL had 12 new highs and gained 44.23% in the last month.
60-month beta of 2.27.
Relative Strength Index (RSI) is at 64.94.
There’s a technical support level around $16.87.
Don’t Forget the Fundamentals
$1.8 billion market capitalization.
Revenue is projected to grow 18.4% this year and another 33.63% next year.
Earnings are estimated to decrease by 20.05% this year but increase again by 13.89% next year.
